Home > Oncology > ASCO 2021 > Gastrointestinal Cancers > Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC

Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC

Presented By
Prof. Dominik Modest, Charité Universitätsmedizin Berlin, Germany
Conference
ASCO 2021
Trial
Phase 3, PANAMA
Progression-free survival in patients with RAS wildtype metastatic colorectal cancer (mCRC) improved with the addition of panitumumab to maintenance therapy with 5-FU/LV versus 5-FU/LV alone, demonstrated results from the phase 3 PANAMA trial. Currently, the preferred maintenance therapy regimen in mCRC is fluoropyrimidine ± bevacizumab, with improved progression-free but not overall survival [1]. Maintenance concepts in the context of EGFR monoclonal antibody-based first-line therapy are still the subject of scientific debate. Although EGFR-antibodies may provide activity during maintenance therapy, 5-FU/LV appears necessary [2]. The phase 3 PANAMA trial (NCT01991873) evaluated the efficacy and safety of maintenance therapy with panitumumab plus 5-FU/LV versus 5-FU/LV alone in patients with RAS wildtype mCRC who showed a clinical ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on